this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Amendments

In the Claims:

Please cancel claim 70 without prejudice or disclaimer and reservation to prosecute the subject matter therein at a later date.

Please substitute the following claim 4 for the pending claim 4:

B1

4. (Once Amended) The isolated nucleic acid molecule of claim 2 wherein said intron is native adenovirus intron 1.

Please substitute the following claim 17 for the pending claim 17:

B2

17. (Once Amended) The cell line of claim 16 wherein said chimeric protein comprises an Ad3 head domain and an Ad5 tail domain or an Ad5 head domain and an Ad3 tail domain.

Please substitute the following claim 41 for the pending claim 41:

B3 cont'd

41. (Once amended) A method for producing an adenovirus particle comprising:

1) providing a packaging cell line wherein said packaging cell line comprises:

a) a stably integrated first nucleic acid molecule operatively linked to a promoter, and said first nucleic acid is operatively linked to a second nucleic acid molecule encoding an adenovirus structural protein, wherein said first nucleic acid molecule comprises an adenovirus tripartite leader (TPL) nucleotide sequence operatively linked to an intron containing an RNA processing signal, said TPL nucleotide sequence comprising (a) first and second different TPL exons or (b) first, second and third different TPL exons, said TPL exons selected from the group consisting of complete TPL exon 1, partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3 and

b) said cell line supports the production of a recombinant adenovirus vector genome by complementation of a deficient viral gene in said vector genome, and

2) producing said adenovirus particle.

Please substitute the following claim 69 for the pending claim 69:

69. (Once amended) The packaging cell line of claim 12 wherein said cell line is selected from the group consisting of 293, A549, W162, HeLa, Vero, 211, 211A and an epithelial cell line wherein said cell line comprises said stably integrated nucleic acid molecule.

Please add the following claims:

95. A method for producing an adenovirus particle comprising:

1) providing a packaging cell line wherein said packaging cell line comprises:

a) a stably integrated first nucleic acid molecule operatively linked to a second nucleic acid molecule encoding an adenovirus structural protein, wherein said first nucleic acid molecule comprises an adenovirus tripartite leader (TPL) nucleotide sequence operatively linked to an intron containing an RNA processing signal, said TPL nucleotide sequence comprising (a) first and second different TPL exons or (b) first, second and third different TPL exons, said TPL exons selected from the group consisting of complete TPL exon 1, partial TPL exon 1, complete TPL exon 2 and complete TPL exon 3 and

b) said cell line supports the production of a recombinant adenovirus vector genome by complementation of a deficient viral gene in said vector genome, and

2) producing said virus particle.

B 5 cont'd.

96. A method for producing an adenovirus particle comprising:

1) providing a packaging cell line wherein said packaging cell line comprises:

a) a stably integrated nucleic acid molecule of claim 1, and

b) said cell line supports the production of a recombinant adenovirus vector genome by complementation of a deficient viral gene in said vector genome, and

2) producing said adenovirus particle.

Sub. E7

97. A method for producing an adenovirus particle comprising:

1) providing a packaging cell line wherein said packaging cell line comprises: the stably integrated nucleic acid molecule of claim 1 and a sequence encoding adenovirus fiber protein, and

2) producing an adenovirus particle.

98. The method of claim 97 wherein said adenovirus particle comprises a genome encoding an exogenous protein.

Sub E10

99. The method of claim 98 wherein said exogenous protein is selected from a group consisting of a tumor-suppressor protein, a biologically active fragment thereof, a suicide protein and a biologically active fragment thereof.

B5 cancld.